HealthTree Podcast for Multiple Myeloma
HealthTree Podcast for Multiple Myeloma brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.
Latest episodes
Feb 19, 2015 • 1h 16min
Myeloma Crowd Radio: Dr. Ajay Nooka, MD, MPH, FACP, Emory Winship CI
Can multiple myeloma be cured by shutting it down before it turns from smoldering to active myeloma? Dr. Ajay Nooka of the Emory Winship Cancer Institute joins us to talk about new, early-stage clinical trials being explored for smoldering myeloma patients including a new OncoPep vaccine to prevent progression.
Jan 29, 2015 • 1h 5min
Myeloma Crowd Radio: Dr. Ravi Vij, MD, Washington University
Are there new treatment options for the relapsed/refractory myeloma patient? Dr. Ravi Vij, MD of Washington University School of Medicine describes some newer approaches and therapies now in clinical trials.
Jan 9, 2015 • 1h 1min
Myeloma Crowd Radio: Dr. Robert Z. Orlowski, MD, PhD MD Anderson Cancer Center
Join us for the first show of 2015 with a review of the ASH conference's most important topics with Dr. Robert Orlowski, MD, PhD, University of Texas MD Anderson Cancer Center. The mPatient Myeloma Radio show change its name to Myeloma Crowd Radio beginning January of 2015. Follow us on Twitter @myelomacrowd or on Facebook at www.facebook.com/myelomacrowd.
Nov 20, 2014 • 1h 6min
mPatient Myeloma Radio: Dr. Vincent Rajkumar, MD, Mayo Clinic
The guidelines for myeloma treatment are changing to allow earlier treatment, even without some of the typical symptoms or disease damage. The goal is to treat earlier and prevent severe damage that myeloma causes. Learn more about these new guidelines from Dr. Vincent Rajkumar, MD of the Mayo Clinic on this very important show.
Nov 14, 2014 • 1h 3min
mPatient Myeloma Radio: Dr. Eric Bartee, MD, PhD, MUSC
When patients harvest stem cells in preparation for autologous transplant, can they be "cleaned up" or can all residual myeloma cells be completely removed before they are given back during transplant? Learn how Dr. Eric Bartee, MD, PhD of the Medical University of South Carolina is using a virus to do just that.
Oct 30, 2014 • 58min
mPatient Myeloma Radio: Dr. Irene Ghobrial MD, PhD, Dana Farber Cancer Institute
Dr. Irene Ghobrial, MD, PhD of the Dana Farber Cancer Institute joins us to explain her recent discovery of a compound that can prevent myeloma from spreading into the bone, protecting patients from one of the most damaging effects of the blood cancer. Join us to learn more about this very exciting discovery.
Oct 3, 2014 • 1h 4min
mPatient Myeloma Radio: Dr. Jesus San Miguel, MD, PhD, University of Navarra
Join us as we talk with renown myeloma expert Dr. Jesus San Miguel of the University Hospital of Salamanca about high risk myeloma, recent findings of the International Myeloma Working Group and his work on minimal residual disease.
Sep 26, 2014 • 1h 5min
mPatient Myeloma Radio: Dr. Larry Kwak, MD, PhD, MD Anderson Cancer Center
Learn from Dr. Larry Kwak, MD, PhD about the latest in immunotherapy; specifically for vaccine use in myeloma. Dr. Kwak was noted on the 2010 Time list of Most Influential People for his vaccine work in lymphoma. As Professor and Chair of the Department of Lymphoma and Myeloma at the University of Texas M.D. Anderson Cancer center, he has 20+ years of experience in cancer vaccines and will share how his success in lymphoma is being advanced in myeloma.
Sep 19, 2014 • 58min
HealthTree Podcast for Multiple Myeloma: Dr. Sarah Holstein, MD, PhD, RPCI
Join us as we talk with Dr. Sarah Holstein, MD, PhD of the Roswell Park Cancer Institute about her work to outsmart myeloma resistance and her work to target the bone marrow microenvironment via a variety of pathways.
Aug 29, 2014 • 1h 19min
HealthTree Podcast for Multiple Myeloma: Dr. Jay Bradner, MD, Dana Farber
Join us as we talk with Dr. Jay Bradner, MD of the Bradner Lab, Dana Farber Cancer Institute and Harvard Medical School. Dr. Bradner focuses his research on the use of chemical biology to target gene regulatory pathways. Specifically, Dr. Bradner is working to develop a MYC inhibitor for myeloma. MYC is the most common translocation to be found in multiple myeloma and increases in prevalance as the disease progresses, so finding a target for this translocations is critical.
